Loading...

REGENXBIO

Nasdaq:RGNX
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RGNX
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The last earnings update was 99 days ago. More info.


Add to Portfolio Compare Print
  • REGENXBIO has significant price volatility in the past 3 months.
RGNX Share Price and Events
7 Day Returns
4.7%
NasdaqGS:RGNX
-0.8%
US Biotechs
0.5%
US Market
1 Year Returns
69.3%
NasdaqGS:RGNX
-1.8%
US Biotechs
2%
US Market
RGNX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
REGENXBIO (RGNX) 4.7% 3.4% -29.9% 69.3% 226.6% -
US Biotechs -0.8% 0.3% 5.7% -1.8% 14.9% 7.1%
US Market 0.5% 6.3% 1.9% 2% 45.1% 40.5%
1 Year Return vs Industry and Market
  • RGNX outperformed the Biotechs industry which returned -1.8% over the past year.
  • RGNX outperformed the Market in United States of America which returned 2% over the past year.
Price Volatility
RGNX
Industry
5yr Volatility vs Market
Related Companies

Value

 Is REGENXBIO undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of REGENXBIO to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for REGENXBIO.

NasdaqGS:RGNX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:RGNX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.43
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.425 (1 + (1- 21%) (0%))
1.425
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.43
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.425 * 7.27%)
13.09%

Discounted Cash Flow Calculation for NasdaqGS:RGNX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for REGENXBIO is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:RGNX DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) -86.00 -36.00 96.00 186.00 225.00
Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Analyst x1
Present Value
Discounted (@ 13.09%)
-76.04 -28.15 66.37 113.71 121.63
Present value of next 5 years cash flows $197.52
NasdaqGS:RGNX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $225.00 × (1 + 2.73%) ÷ (13.09% – 2.73%)
$2,230.88
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $2,230.88 ÷ (1 + 13.09%)5
$1,205.97
NasdaqGS:RGNX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $197.52 + $1,205.97
$1,403.49
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,403.49 / 35.84
$39.16
NasdaqGS:RGNX Discount to Share Price
Calculation Result
Value per share (USD) From above. $39.16
Current discount Discount to share price of $45.37
= -1 x ($45.37 - $39.16) / $39.16
-15.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of REGENXBIO is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for REGENXBIO's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are REGENXBIO's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:RGNX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $2.47
NasdaqGS:RGNX Share Price ** NasdaqGS (2019-02-13) in USD $45.37
United States of America Biotechs Industry PE Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 20.45x
United States of America Market PE Ratio Median Figure of 3,046 Publicly-Listed Companies 16.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of REGENXBIO.

NasdaqGS:RGNX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RGNX Share Price ÷ EPS (both in USD)

= 45.37 ÷ 2.47

18.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO is good value based on earnings compared to the US Biotechs industry average.
  • REGENXBIO is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does REGENXBIO's expected growth come at a high price?
Raw Data
NasdaqGS:RGNX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 18.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-104%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 25 Publicly-Listed Biotechs Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

NasdaqGS:RGNX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 18.36x ÷ -104%

-0.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on REGENXBIO's assets?
Raw Data
NasdaqGS:RGNX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $13.84
NasdaqGS:RGNX Share Price * NasdaqGS (2019-02-13) in USD $45.37
United States of America Biotechs Industry PB Ratio Median Figure of 404 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,122 Publicly-Listed Companies 1.81x
NasdaqGS:RGNX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RGNX Share Price ÷ Book Value per Share (both in USD)

= 45.37 ÷ 13.84

3.28x

* Primary Listing of REGENXBIO.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • REGENXBIO is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess REGENXBIO's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. REGENXBIO has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is REGENXBIO expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-104%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is REGENXBIO expected to grow at an attractive rate?
  • REGENXBIO's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • REGENXBIO's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • REGENXBIO's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:RGNX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:RGNX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -104%
NasdaqGS:RGNX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts -34.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 19.8%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:RGNX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:RGNX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 246
2022-12-31 206
2021-12-31 113
2020-12-31 126 -22 -79 3
2019-12-31 23 -73 -123 4
2018-12-31 201 104 103 4
NasdaqGS:RGNX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 180 95 80
2018-06-30 176 97 78
2018-03-31 142 18 53
2017-12-31 10 -58 -73
2017-09-30 10 -65 -77
2017-06-30 9 -59 -74
2017-03-31 5 -58 -74
2016-12-31 5 -49 -63
2016-09-30 7 -33 -49
2016-06-30 8 -29 -38
2016-03-31 7 -29 -32
2015-12-31 8 -23 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • REGENXBIO's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • REGENXBIO's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:RGNX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from REGENXBIO Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:RGNX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -2.00 -0.62 -3.37 2.00
2019-12-31 -3.31 -2.94 -3.54 3.00
2018-12-31 2.97 4.24 2.20 3.00
NasdaqGS:RGNX Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 2.47
2018-06-30 2.48
2018-03-31 1.71
2017-12-31 -2.45
2017-09-30 -2.68
2017-06-30 -2.69
2017-03-31 -2.80
2016-12-31 -2.38
2016-09-30 -1.84
2016-06-30 -1.80
2016-03-31 -2.12
2015-12-31 -2.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if REGENXBIO will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess REGENXBIO's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
REGENXBIO has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has REGENXBIO performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare REGENXBIO's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • REGENXBIO's year on year earnings growth rate has been positive over the past 5 years.
  • REGENXBIO has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • REGENXBIO has become profitable in the last year making it difficult to compare the US Biotechs industry average.
Earnings and Revenue History
REGENXBIO's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from REGENXBIO Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:RGNX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 179.77 79.63 30.51
2018-06-30 175.80 78.13 30.95
2018-03-31 142.33 53.06 28.99
2017-12-31 10.39 -73.17 27.23
2017-09-30 10.05 -76.78 28.16
2017-06-30 8.84 -74.23 24.92
2017-03-31 4.65 -74.19 24.73
2016-12-31 4.59 -62.97 23.59
2016-09-30 7.34 -48.54 22.09
2016-06-30 8.35 -37.72 18.45
2016-03-31 7.34 -32.07 15.68
2015-12-31 7.59 -23.80 11.91
2015-09-30 4.29 -21.18 8.79
2015-06-30 3.64 -15.76 7.30
2015-03-31 3.83 -7.53 4.93
2014-12-31 6.12 -4.82 3.85
2013-12-31 6.09 -5.81 5.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • REGENXBIO has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • REGENXBIO used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
  • REGENXBIO has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess REGENXBIO's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
REGENXBIO has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is REGENXBIO's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up REGENXBIO's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • REGENXBIO is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • REGENXBIO's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of REGENXBIO's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • REGENXBIO has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from REGENXBIO Company Filings, last reported 4 months ago.

NasdaqGS:RGNX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 494.06 0.00 372.59
2018-06-30 317.22 0.00 286.49
2018-03-31 299.34 0.00 229.87
2017-12-31 183.03 0.00 160.78
2017-09-30 194.65 0.00 166.66
2017-06-30 211.70 0.00 162.08
2017-03-31 212.90 0.00 145.81
2016-12-31 161.74 0.00 89.55
2016-09-30 180.23 0.00 91.77
2016-06-30 196.18 0.00 94.21
2016-03-31 208.60 0.00 101.06
2015-12-31 216.81 0.00 114.14
2015-09-30 221.81 0.00 213.35
2015-06-30 82.63 0.00 85.22
2015-03-31 20.20 0.00 25.37
2014-12-31 -5.70 3.83 1.12
2013-12-31 -2.14 0.66 1.12
  • REGENXBIO has no debt.
  • REGENXBIO currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • REGENXBIO has no debt, it does not need to be covered by operating cash flow.
  • REGENXBIO has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess REGENXBIO's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. REGENXBIO has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is REGENXBIO's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from REGENXBIO dividends. Estimated to be 0% next year.
If you bought $2,000 of REGENXBIO shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate REGENXBIO's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate REGENXBIO's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:RGNX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:RGNX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as REGENXBIO has not reported any payouts.
  • Unable to verify if REGENXBIO's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of REGENXBIO's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as REGENXBIO has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of REGENXBIO's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess REGENXBIO's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can REGENXBIO afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. REGENXBIO has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of REGENXBIO's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ken Mills
COMPENSATION $2,543,136
AGE 43
TENURE AS CEO 9.9 years
CEO Bio

Mr. Kenneth T. Mills, also known as Ken, has been the Chief Executive Officer and President at REGENXBIO Inc. since March 2009. Mr. Mills served as the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, where he worked as part of the founding management establish its operations and ongoing business strategy. As part of his responsibilities, Mr. Mills supervised all company affairs, including direct management of corporate and business development, strategic planning, as well as finance and accounting activities. Mr. Mills has been a Director of REGENXBIO Inc. since March 2009. He served as a Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

CEO Compensation
  • Ken's compensation has been consistent with company performance over the past year.
  • Ken's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the REGENXBIO management team in years:

2.5
Average Tenure
48.5
Average Age
  • The tenure for the REGENXBIO management team is about average.
Management Team

Ken Mills

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
43
TENURE
9.9 yrs

Vit Vasista

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
50
TENURE
9.5 yrs

Olivier Danos

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
60
TENURE
1.9 yrs

Curran Simpson

TITLE
Senior Vice President of Technical Operations
COMPENSATION
$1M
AGE
56
TENURE
3.5 yrs

Patrick Christmas

TITLE
Senior VP & General Counsel
AGE
47
TENURE
2.5 yrs

Andrew Yost

TITLE
Vice President of Corporate Development
TENURE
1.9 yrs

Shiva Fritsch

TITLE
Senior Vice President of Human Resources
TENURE
1.3 yrs

Laura Coruzzi

TITLE
Senior Vice President of Intellectual Property
TENURE
2.8 yrs

Ram Palanki

TITLE
Senior VP of Commercial Strategy & Operations
TENURE
0.5 yrs

Sara Berl

TITLE
Vice President of Law and Policy
AGE
42
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the REGENXBIO board of directors in years:

3.8
Average Tenure
64.5
Average Age
  • The tenure for the REGENXBIO board of directors is about average.
Board of Directors

Don Hayden

TITLE
Chairman of the Board
COMPENSATION
$228K
AGE
62
TENURE
6 yrs

Ken Mills

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
43
TENURE
9.9 yrs

Luke Beshar

TITLE
Independent Director
COMPENSATION
$208K
AGE
59
TENURE
3.8 yrs

Jerry Karabelas

TITLE
Independent Director
COMPENSATION
$196K
AGE
66
TENURE
3.8 yrs

Allan Fox

TITLE
Director
COMPENSATION
$188K
AGE
70
TENURE
10 yrs

Judith Swain

TITLE
Member of Scientific Advisor
AGE
69

Inder Verma

TITLE
Member of Scientific Advisor
AGE
70

Dave Stump

TITLE
Independent Director
COMPENSATION
$200K
AGE
68
TENURE
3.3 yrs

Dan Abdun-Nabi

TITLE
Independent Director
COMPENSATION
$196K
AGE
63
TENURE
2.5 yrs

Daniel Tassé

TITLE
Independent Director
COMPENSATION
$193K
AGE
58
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess REGENXBIO's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. REGENXBIO has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did REGENXBIO Inc. (NASDAQ:RGNX) Use Debt To Deliver Its ROE Of 16%?

Our data shows REGENXBIO has a return on equity of 16% for the last year. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.16 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is REGENXBIO Inc. (NASDAQ:RGNX) Worth US$43.81 Based On Intrinsic Value?

by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Is REGENXBIO Inc. (NASDAQ:RGNX) A Financially Sound Company?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does RGNX's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt

Simply Wall St -

REGENXBIO Inc (NASDAQ:RGNX): Financial Strength Analysis

Surprisingly though, when accounted for risk, mid-caps have delivered better returns compared to the two other categories of stocks. … This article will examine RGNX’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Don’t forget that this is a general and concentrated examination of REGENXBIO's financial health, so you should conduct further analysis.

Simply Wall St -

What Does REGENXBIO Inc's (NASDAQ:RGNX) PE Ratio Tell You?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to learn about the link between company’s fundamentals and stock market performance. … While RGNX might seem like an attractive stock to buy, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions.

Simply Wall St -

Is REGENXBIO Inc's (NASDAQ:RGNX) CEO Pay Fair?

Recognizing whether CEO incentives are aligned with shareholders is a crucial part of investing. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … CEOs leading companies of similar size and profitability

Simply Wall St -

Why REGENXBIO Inc's (NASDAQ:RGNX) ROE Of 17.73% Does Not Tell The Whole Story

This analysis is intended to introduce important early concepts to people who are starting to invest. … and want to start learning about core concepts of fundamental analysis on practical examples from today's market. … See our latest analysis for REGENXBIO

Simply Wall St -

REGENXBIO Inc (NASDAQ:RGNX): What Can We Expect From Future Profit Margins?

With analysts projecting … in earnings of -3.08% annualised … it's important to take a step back

Simply Wall St -

With A -16.20% Earnings Drop, Is REGENXBIO Inc's (NASDAQ:RGNX) A Concern?

I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … This doesn’t seem to paint a better picture, as earnings seem to have steadily been getting more and more negative over time. … You should continue to research REGENXBIO to get a better picture of the stock by looking at: 1.

Simply Wall St -

Is Regenxbio Inc (NASDAQ:RGNX) As Financially Strong As Its Balance Sheet Indicates?

Regenxbio Inc (NASDAQ:RGNX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … See our latest analysis for Regenxbio Does RGNX's growth rate justify its decision for financial flexibility over lower cost of capital? … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Company Info

Map
Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Details
Name: REGENXBIO Inc.
RGNX
Exchange: NasdaqGS
Founded: 2008
$1,626,077,087
35,840,359
Website: http://www.regenxbio.com
Address: REGENXBIO Inc.
9600 Blackwell Road,
Suite 210,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RGNX Common Shares Nasdaq Global Select US USD 17. Sep 2015
DB RB0 Common Shares Deutsche Boerse AG DE EUR 17. Sep 2015
Number of employees
Current staff
Staff numbers
139
REGENXBIO employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/14 01:07
End of day share price update: 2019/02/13 00:00
Last estimates confirmation: 2019/02/06
Last earnings filing: 2018/11/07
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.